Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.39 |
| ▸ | WDR91 | A4D1P6 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 5/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1173867 | 0.90 | HDAC6 (0.66) | HDAC6HDAC8WDR91KDM1AHDAC3 | |
| SCHEMBL1173979 | 0.90 | HDAC6 (0.66) | HDAC6HDAC8KDM1AHDAC3HDAC1 | |
| SCHEMBL7797509 | 0.75 | HDAC6 (0.46) | HDAC6HDAC8KDM1AHDAC3HDAC1 | |
| SCHEMBL12883329 | 0.74 | HDAC6 (0.47) | HDAC6HDAC8KDM4EMEN1KMT2A | |
| SCHEMBL1174045 | 0.72 | HDAC6 (0.78) | HDAC6HDAC8KDM1AHDAC1KDM4E | |
| SCHEMBL7865719 | 0.72 | HDAC6 (0.53) | HDAC6HDAC8HDAC3HDAC1 | |
| SCHEMBL1263310 | 0.71 | HDAC6 (0.54) | HDAC6HDAC8HDAC3HDAC1 | |
| SCHEMBL12210615 | 0.69 | HDAC6 (1.00) | HDAC6HDAC8HDAC3HDAC1 | |
| SCHEMBL1174178 | 0.68 | HDAC6 (0.62) | HDAC6HDAC8HDAC3HDAC1 | |
| SCHEMBL1174737 | 0.68 | HDAC6 (1.00) | HDAC6HDAC8KDM1AHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329836-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329836-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC5, HDAC1 | HDAC6 1/4885HDAC8 11/4885WDR91 458/4885 |
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | HDAC6, HDAC5, HDAC1 | HDAC6 1/4885HDAC8 11/4885WDR91 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.